FDA Panel Recommends Easing Access to Peptides Amid Safety Concerns
An FDA advisory panel has narrowly recommended easing restrictions on several peptides, despite concerns from FDA scientists about their safety and efficacy. The panel voted 8-6 in favor of allowing pharmacies to compound peptides like BPC-157 and TB-500, which are popular among wellness influencers. The decision comes amid debates over the lack of human studies and potential risks associated with these substances. The FDA will review the panel's recommendations, which are not binding, before making a final decision. The outcome could impact the availability and regulation of peptides in the U.S. 
